TG Therapeutics' strong cash position and Briumvi success fuel growth potential. Find out why TGTX stock is rated a strong ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. This ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...

The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.

Patients with pancreatic cancer who participate in clinical research have better outcomes. PanCAN strongly recommends clinical trials at diagnosis and during every treatment decision. Clinical trials ...

Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected ...

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic SclerosisTEL AVIV, Israel, ...

Italfarmaco S.p.A. today announced a comprehensive update on the regulatory and clinical advancements for givinostat, the company’s drug for the treat ...

Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two pa ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.